Pfizer (PFE) Misses Q3 EPS by 9c; Reaffirms FY Outlook

Pfizer (NYSE: PFE) reported Q3 EPS of ($0.17), $0.09 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $13.2 billion versus the consensus estimate of $13.33 billion.

GUIDANCE:

Pfizer sees FY2023 EPS of $1.45-$1.65, versus the consensus of $1.50. Pfizer sees FY2023 revenue of $58-61 billion, versus the consensus of $55.37 billion.

For earnings history and earnings-related data on Pfizer (PFE) click here.

You May Also Be Interested In

• Pfizer's Litfulo meets Phase 3 endpoints for vitiligo treatment
• Florida attorney general sues Pfizer over COVID-19 vaccine marketing claims
• Rivian reports record Q3 deliveries, beats estimates, shares rise